Wednesday, July 8, 2026

pharma · Malaria · Pharmacokinetics · CNSP

CNS Pharmaceuticals

CNS Pharmaceuticals is a pharma organization headquartered in Houston, USA. It trades on NYSE under ticker CNSP. Primary therapeutic focus areas include Malaria, Pharmacokinetics, Ovarian Cancer, Glioblastoma multiforme

Houston, TX 77027, US HQ
2017 Founded
12 Employees
Public company Type
CNSP · NYSE Ticker
Company details
Status
Public
HQ
Houston, TX 77027, US
Founded
2017
Employees
12
Programs
21
Drugs
18
Patents
0

Quick answer

CNS Pharmaceuticals is a pharma organization headquartered in Houston, USA. It trades on NYSE under ticker CNSP. Primary therapeutic focus areas include Malaria, Pharmacokinetics, Ovarian Cancer, Glioblastoma multiforme (GBM), Glioblastoma Multiforme, Adult. NovaPharmaNews links 21 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 2 (11), phase 1 (9), phase 3 (1).

Company snapshot

CNS Pharmaceuticals is a biotechnology company focused on developing innovative therapies for serious diseases in neurology and oncology. With an experienced executive team and a focus on high-value therapeutic opportunities, the Company is working to build a differentiated portfolio of therapies addressing significant unmet medical needs. CNS Pharmaceuticals is committed to advancing novel treatm

  • 21 active pipeline program(s) linked via ClinicalTrials.gov.
  • 21 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for CNS Pharmaceuticals. Not investment advice.

Lead pipeline drugs

Active clinical programs

Momentum

Proprietary activity score for CNS Pharmaceuticals.

1 active signal

20 /100 +0 vs 30 days ago

Signal breakdown

  • Clinical trials 21 30d
  • Nova articles 0 30d
  • Patents filed 0 30d
  • FDA actions 0 30d
  • SEC filings 0 30d
  • Conference presentations 0 90d
  • Pipeline advances 0 30d

Competitor landscape

Therapeutic-area overlap peers from registry and pipeline signals.

Recent activity

Latest pipeline, patent, and corporate events for CNS Pharmaceuticals.

  1. Clinical update

    9941 — Phase 2

  2. Clinical update

    Sertraline+Antibiotic (penicillin/azithromycin) — Phase 2

  3. Clinical update

    PRA — Phase 1

  4. Clinical update

    DAB — Phase 1

  5. Clinical update

    (+)-SJ000557733 — Phase 1

View all clinical trial activity →

Quick answers

Common questions about this sponsor — for analysts and search.

  • What is CNS Pharmaceuticals?

    CNS Pharmaceuticals is a pharma organization headquartered in Houston, USA. It trades on NYSE under ticker CNSP. Primary therapeutic focus areas include Malaria, Pharmacokinetics, Ovarian Cancer, Glioblastoma multiforme (GBM), Glioblastoma Multiforme, Adult. NovaPharmaNews links

  • Is CNS Pharmaceuticals publicly traded?

    Yes. CNS Pharmaceuticals is listed with ticker CNSP on NYSE per SEC EDGAR records linked on this profile.

  • What drugs does CNS Pharmaceuticals develop or market?

    We link 18 drug profile(s) where CNS Pharmaceuticals is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/cns-pharmaceuticals#company-drugs.

  • What are the latest developments for CNS Pharmaceuticals?

    In the last 12 months our linked public records show 21 trial program update(s) and 0 US patent grant(s) tied to this profile.

  • What therapeutic areas does CNS Pharmaceuticals focus on?

    CNS Pharmaceuticals focuses on Malaria, Pharmacokinetics, Ovarian Cancer based on our analysis of their pipeline programs and drug development activities.

Therapeutic focus

Therapeutic area distribution

Pipeline concentration by therapeutic area from linked clinical programs.

Programs by therapeutic area

Others
30
Oncology
5
Neurology
1